The year in cardiovascular medicine 2021: dyslipidaemia

Creative Commons License

Tokgozoglu L., Orringer C., Ginsberg H. N., Catapano A. L.

EUROPEAN HEART JOURNAL, vol.43, no.8, pp.807-818, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 8
  • Publication Date: 2022
  • Doi Number: 10.1093/eurheartj/ehab875
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.807-818
  • Keywords: Cardiovascular diseases, Lipids, Nucleic acid therapeutics, RNA interference, Antisense, CRISPR, LDL-C, Triglycerides, Lp(a), Statins, PCSK9 inhibitors, FAMILIAL HYPERCHOLESTEROLEMIA, LIPOPROTEIN(A) LEVELS, STATIN THERAPY, TRIGLYCERIDES, CHOLESTEROL, INHIBITION, EVINACUMAB, RISK, INCLISIRAN, PLACEBO
  • Hacettepe University Affiliated: Yes


The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.